Xiamen Humanity Hospital
Ovarian cancer treatment cost in China typically includes diagnostics like a PET-CT and primary procedures such as ovarian cancer surgery which runs $17,500 to $33,500. Other options like chemotherapy for ovarian cancer range from $22,000 to $48,000. Total expenses depend on the cancer stage and hospital type. Patients often find 40-70% savings compared to the US. Top cities for treatment include Guangzhou and Xiamen.
Typical Ovarian Cancer Treatment Costs in China
Bookimed Expert Insight: Advanced stage patients find significant value at JCI-accredited centers like Fuda Cancer Hospital. This facility specializes in late-stage cases using NanoKnife and cryosurgery technologies. For precision radiation, Xiamen Humanity Hospital is optimal due to Professor Liu Shi Xin's expertise. These specialized centers offer integrated care that often reduces the need for multiple hospital transfers.
| China | Turkey | Austria | |
| Оophorectomy | from $7,800 | from $2,943 | from $15,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Ovarian cancer surgery | from $17,500 | from $9,243 | from $25,000 |
| Omentectomy | from $6,500 | from $4,500 | from $15,000 |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | from $22,500 | from $22,500 | from $40,000 |
Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.
Professor Zheng Qiu Hong is Director of the Cell Therapy Research Center and a National Senior Expert in Biotherapy. He is a Professor and Master’s Supervisor at Fujian Medical University. He has more than 30 years of clinical experience in tumor molecular biology and biotherapy. From 2012 to 2013, he was a visiting scholar in stem cell research at the University of Connecticut School of Life Sciences. He previously held leadership roles at Fujian Cancer Hospital. These roles included Director of the Tumor Molecular Biology Laboratory and Director of the Surgical Oncology Research Laboratory. He also served as Deputy Director of the Fujian Key Laboratory of Tumor Biotherapy and Deputy Director of the Biotherapy and Immunotherapy Center.
Appointments include Standing Committee Member of the Biotherapy Committee of the Chinese Research Hospital Association. He is also a Committee Member of the Tumor Immunology and Biotherapy Committee of the Chinese Society for Immunology. In addition, he is Deputy Chair of the Academic Committee of the Xiamen Cell Therapy Research Center at the First Affiliated Hospital of Xiamen University.
Dr. Niu Lizhi is the President and chief surgeon at Fuda Cancer Hospital in Guangzhou. He has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures. Dr. Niu specializes in minimally invasive oncology for lung, pancreatic, and liver cancers. He treats patients ranging from early childhood through age 94.
Ovarian cancer treatment in China integrates cytoreductive surgery with platinum-based chemotherapy and maintenance therapies. Specialized centers combine Western protocols with Traditional Chinese Medicine to manage side effects. Advanced options like HIPEC, CyberKnife M6 radiosurgery, and Natural Killer cell therapy are available for complex or recurrent cases.
Bookimed Expert Insight: China is a global leader in combining traditional hospital stays with high-tech outpatient oncology. A package at Jinshazhou Hospital of Guangzhou University of Chinese Medicine costs approximately $7,750 for CyberKnife M6. This includes transfers and medications but excludes hospital nights. This model allows patients to receive advanced radiation while staying in more comfortable local accommodations.
Patient Consensus: Patients emphasize the importance of early genetic testing for BRCA status to access targeted therapies. Many note that high-volume hospitals in Guangzhou offer shorter wait times than public facilities in other regions.
Innovative maintenance therapies for ovarian cancer in China focus on targeted agents and cellular treatments. These include PARP inhibitors like olaparib and niraparib to repair DNA gaps. Anti-angiogenesis inhibitors and novel immunotherapies, including NK cell therapy, are also used within JCI-accredited facilities.
Bookimed Expert Insight: Genetic testing for BRCA and HRD markers is essential before selecting maintenance protocols. Chinese-manufactured PARP inhibitors offer similar efficacy to international brands at approximately 30% of the cost. Patients should verify if their package includes genomic profiling to ensure the therapy fits their profile.
Patient Consensus: Patients highlight that starting maintenance post-chemotherapy and managing fatigue are vital for long-term health. Many emphasize tracking CA-125 levels monthly to adjust therapy quickly if indicators change.
China offers advanced minimally invasive treatments for ovarian cancer, including NanoKnife (irreversible electroporation), cryosurgery, and microwave hyperthermal therapy. Specialized centers utilize CyberKnife M6 radiosurgery and DaVinci robotic systems for precise tumor removal. These ablative techniques target diseased tissue while preserving healthy surrounding organs.
Bookimed Expert Insight: While many countries focus on traditional debulking, Chinese JCI-accredited facilities like Fuda Cancer Hospital specialize in combining multiple minimally invasive therapies. Our data shows these centers often treat late-stage cases using a `3C` approach: cryosurgery, cancer microvascular intervention, and combined immunotherapy. This multimodal strategy is aimed at patients who are not candidates for conventional open surgery.
Patient Consensus: Patients note that while recovery from these ablative procedures is often faster than traditional surgery, it is vital to confirm long-term data. Some emphasize that these `miracle` options require careful screening to ensure they suit specific cancer stages.
The 5-year survival rate for ovarian cancer in China is approximately 43.7% in top centers. This baseline varies by cancer stage and patient age. Pediatric and adolescent cases show higher survival reaching 77.2%. Urban oncology centers consistently report better outcomes than rural facilities.
Bookimed Expert Insight: Patient volume is a major indicator of quality in Chinese oncology. Fuda Cancer Hospital serves over 30,000 patients from 100 countries. This high volume allows surgeons to master specific skills like cryosurgery. A CyberKnife M6 package from Jinshazhou Hospital costs approximately $7,750 (56,000 CNY). These bundles often include VIP transfers and doctor consultations which streamline complex medical travel.
Patient Consensus: Patients note that arriving at a specialized center quickly is vital for success. Many travelers recommend verifying a surgeon's specific volume in procedures like debulking before starting treatment.
International patients should plan to stay in China for 2 to 4 weeks after ovarian cancer surgery. This duration ensures initial wound stability and proper recovery. Most patients require 5 to 10 days of hospitalization. A further 14 days of local monitoring helps prevent complications for long-haul travel.
Bookimed Expert Insight: JCI-accredited facilities like Fuda Cancer Hospital focus on minimally invasive therapies that often reduce recovery times. While standard surgery requires a long stay, CyberKnife M6 packages available in Guangzhou include hotel stays and transfers. This coordination helps patients manage the transition from clinical care to travel readiness without logistical delays.
Patient Consensus: Patients note that hospitals may discharge you within 10 days. They emphasize booking a hotel nearby for another 2 weeks to handle follow-up care and pain management before flying home.
Medical tourism treatment packages bundle clinical procedures with essential travel logistics. They typically include surgery or radiosurgery, professional medical fees, and hospital facility charges. Most comprehensive options also provide ground transportation, bilingual coordination, and local accommodation to ensure a seamless healthcare experience.
Bookimed Expert Insight: China's leading oncology centers often prioritize specialized technology over standard hotel inclusions. For example, Jinshazhou Hospital offers advanced CyberKnife M6 radiosurgery with clinic transfers. However, their 56,000 CNY (approximately $7,850) oncology packages may not include hotel nights. Always check if accommodation is bundled or offered as an add-on.
Patient Consensus: Patients note it is important to budget extra for unexpected scans or extended recovery days. Many suggest getting all inclusions in writing to avoid surprises after arrival.
Identifying a high-quality cancer hospital in China requires selecting Grade 3-A institutions or JCI-accredited centers in medical hubs like Guangzhou, Beijing, or Shanghai. Prioritize facilities specializing in advanced oncology services, including robotic surgery, HIPEC, and minimally invasive treatments like cryosurgery or NanoKnife.
Bookimed Expert Insight: While public Tier-1 hospitals are excellent, international patients often face long admission waitlists. Data shows JCI-accredited facilities in Guangzhou, like Fuda Cancer Hospital, cater specifically to global arrivals with dedicated coordination. Choosing a clinic that offers bundled packages, such as Jinshazhou Hospital’s CyberKnife program for approximately $7,800, often includes necessary transfers and hotel stays that public hospitals rarely provide.
Patient Consensus: Patients emphasize choosing top-tier public hospitals in major cities to avoid quality variations. Many suggest hiring a personal translator for smoother navigation even within international departments.
Chinese oncology centres offer technologies including CyberKnife M6 radiosurgery, DaVinci robotic systems, and HIPEC for ovarian cancer. These precision tools allow specialists to target tumours while sparing healthy tissue. Leading facilities like Fuda Cancer Hospital also provide minimally invasive ablative therapies and immunotherapy.
Bookimed Expert Insight: Many centres focus on chemotherapy. However, Fuda Cancer Hospital specialises in over 10 types of minimally invasive alternatives. Their experts have treated 30,000+ patients from 100 countries. This high volume often leads to better outcomes in complex, late-stage cases.
Non-invasive options like CyberKnife and Gamma Knife are available in China for ovarian cancer. These stereotactic radiosurgery systems treat solid tumours without incisions. Specialised centres in Guangzhou and Xiamen use these technologies for precise ablation. They are often used for managing metastatic lesions or inoperable cases.
Bookimed Expert Insight: CyberKnife M6 packages in Guangzhou cost approximately A$11,200. This price typically includes video consultations and local transfers. Data shows these technologies are frequently used for abdominal metastases. Dr Zhang Yanjun and Prof. Dr Liu Shi Xin lead these precision radiation programmes.
Patient Consensus: Patients note that Gamma Knife is usually for brain metastases. They suggest confirming if radiosurgery targets the primary tumour or spread. It is helpful to request the treatment intent in writing before travelling to China.
Recognised medical centres in China for ovarian cancer include Fuda Cancer Hospital in Guangzhou and Jinshazhou Hospital. These centres specialise in immunotherapy and minimally invasive technologies. Facilities often hold international JCI accreditation. They provide multidisciplinary care for complex or late-stage cases.
Bookimed Expert Insight: Major centres offer CyberKnife M6 for approximately A$11,200. The real value for Australians is the teleconsultation inclusion. This lets patients review pathology with national oncology committee members like Dr Zhang Yanjun. It confirms the treatment plan is suitable without initial travel costs.
Patient Consensus: Patients recommend choosing large specialist centres in Guangzhou or Beijing with multidisciplinary teams. They note that on-site pathology and dedicated gynaecologic oncology units are vital. These help with managing complex surgery and chemotherapy.